<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:arxiv="http://arxiv.org/schemas/atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title>q-bio.TO updates on arXiv.org</title>
    <link>http://rss.arxiv.org/rss/q-bio.TO</link>
    <description>q-bio.TO updates on the arXiv.org e-print archive.</description>
    <atom:link href="http://rss.arxiv.org/rss/q-bio.TO" rel="self" type="application/rss+xml"/>
    <docs>http://www.rssboard.org/rss-specification</docs>
    <language>en-us</language>
    <lastBuildDate>Tue, 30 Sep 2025 04:01:04 +0000</lastBuildDate>
    <managingEditor>rss-help@arxiv.org</managingEditor>
    <pubDate>Tue, 30 Sep 2025 00:00:00 -0400</pubDate>
    <skipDays>
      <day>Sunday</day>
      <day>Saturday</day>
    </skipDays>
    <item>
      <title>Effectiveness and Safety of Selective IL-23 Receptor Antagonists in Moderate to Severe Ulcerative Colitis: A Systematic Review, Meta-Analysis and Trial Sequential Analysis</title>
      <link>https://arxiv.org/abs/2509.25069</link>
      <description>arXiv:2509.25069v1 Announce Type: new 
Abstract: Selective interleukin-23 receptor antagonists (IL-23RA) show promise for treating moderate to severe ulcerative colitis (UC) but their efficacy and safety are not fully understood. We performed a systematic review and meta-analysis of randomized controlled trials comparing IL-23RA with placebo in moderate to severe UC. Outcomes included clinical and endoscopic remission, response rates, and adverse events. Nine trials including 3808 patients in the induction phase and 1734 in the maintenance phase were analyzed. IL-23RA improved clinical remission (induction risk ratio 2.63, 95 percent confidence interval 2.05-3.36; maintenance 1.99, 95 percent confidence interval 1.63-2.44) and endoscopic remission (induction 2.36, 95 percent confidence interval 1.70-2.20; maintenance 1.96, 95 percent confidence interval 1.63-2.37). IL-23RA reduced serious adverse events in the induction phase (0.40, 95 percent confidence interval 0.27-0.69) with no difference during maintenance (0.75, 95 percent confidence interval 0.31-1.84). No significant differences were observed in overall adverse events or specific events such as headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-23RA showed superior effectiveness and similar safety compared with placebo in moderate to severe UC.</description>
      <guid isPermaLink="false">oai:arXiv.org:2509.25069v1</guid>
      <category>q-bio.TO</category>
      <pubDate>Tue, 30 Sep 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>new</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Wellgner Fernandes Oliveira Amador, Isabelle Castro Vitor, Milena Ramos Tome, Diogo Delgado Dotta, Rodrigo V Motta</dc:creator>
    </item>
    <item>
      <title>MAE-SAM2: Mask Autoencoder-Enhanced SAM2 for Clinical Retinal Vascular Leakage Segmentation</title>
      <link>https://arxiv.org/abs/2509.10554</link>
      <description>arXiv:2509.10554v4 Announce Type: replace 
Abstract: We propose MAE-SAM2, a novel foundation model for retinal vascular leakage segmentation on fluorescein angiography images. Due to the small size and dense distribution of the leakage areas, along with the limited availability of labeled clinical data, this presents a significant challenge for segmentation tasks. Our approach integrates a Self-Supervised learning (SSL) strategy, Masked Autoencoder (MAE), with SAM2. In our implementation, we explore different loss functions and conclude a task-specific combined loss. Extensive experiments and ablation studies demonstrate that MAE-SAM2 outperforms several state-of-the-art models, achieving the highest Dice score and Intersection-over-Union (IoU). Compared to the original SAM2, our model achieves a $5\%$ performance improvement, highlighting the promise of foundation models with self-supervised pretraining in clinical imaging tasks.</description>
      <guid isPermaLink="false">oai:arXiv.org:2509.10554v4</guid>
      <category>q-bio.TO</category>
      <category>eess.IV</category>
      <pubDate>Tue, 30 Sep 2025 00:00:00 -0400</pubDate>
      <arxiv:announce_type>replace</arxiv:announce_type>
      <dc:rights>http://arxiv.org/licenses/nonexclusive-distrib/1.0/</dc:rights>
      <dc:creator>Xin Xing, Irmak Karaca, Amir Akhavanrezayat, Samira Badrloo, Quan Dong Nguyen, Mahadevan Subramaniam</dc:creator>
    </item>
  </channel>
</rss>
